Founder.page ↗
Clicks.page ↗Colossal Biosciences
Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platform technologies for conservation and medicine.
- Founded
- 2021
- Category
- AI
- Funding
- VC-backed
Every fact above is shown only where it could be checked against a source: funding against a primary source, backers against the investor’s own directory, and a location only where the company names that city on its own site. A row that is absent is one we could not source, not a zero. The summary is a written description of the company. Category is our own classification. Spotted something wrong? Tell us.
Frequently asked questions
What does Colossal Biosciences do?
Colossal Biosciences is using CRISPR gene editing to de-extinct the woolly mammoth, thylacine (Tasmanian tiger), and dodo. Beyond de-extinction, their breakthroughs in gene editing and cold-weather biology create platform technologies for conservation and medicine.
Where is Colossal Biosciences based?
Location for Colossal Biosciences has not been disclosed publicly.
When was Colossal Biosciences founded?
Colossal Biosciences was founded in 2021.
How much has Colossal Biosciences raised?
Colossal Biosciences is vc-backed. Funding details have not been disclosed.